A review on the role of carnitine in the management of tamoxifen side effects in treated women with breast cancer

被引：12
作者：
El-Ashmawy, Nahla E. [1 ]
Khalil, Rania M. [2 ]
机构：
[1] Tanta Univ, Dept Biochem, Fac Pharm, Tanta, Egypt
[2] Delta Univ, Dept Biochem, Fac Pharm, Gamasah, Egypt
来源：
TUMOR BIOLOGY | 2014年 / 35卷 / 04期
关键词：
Breast cancer; Cancer prognosis; L-carnitine; Resistance; Side effects; Tamoxifen; ACETYL-L-CARNITINE; RANDOMIZED DOUBLE-BLIND; PROPIONYL-L-CARNITINE; FATTY-ACID SYNTHASE; GROWTH-FACTOR-I; POSTMENOPAUSAL WOMEN; OXIDATIVE STRESS; DEPRESSED MOOD; HUMAN CORNEAL; FATIGUE;
D O I：
10.1007/s13277-013-1477-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
l-carnitine is an antioxidant and is found to be a protective agent against many diseases including cancer. This review illustrates the possible role of l-carnitine as an add-on therapy to breast cancer patients maintained on tamoxifen. The objectives of carnitine treatment are diverse: improving tamoxifen-related side effects, offering better cancer prognosis by reducing the risk of developing cancer recurrence or metastasis, and modulating the growth factors which may be, in part, a prospective illustration to overcome tamoxifen resistance. So, it could be recommended to supplement l-carnitine to breast cancer patients starting tamoxifen treatment.
引用
收藏
页码：2845 / 2855
页数：11
相关论文
共 50 条
  • [41] The impact of tamoxifen treatment on voice parameters in premenopausal women with breast cancer
    Ata, Serdar
    Ekici, Nur Yuecel
    Buyuksimsek, Mahmut
    Cil, Timucin
    Duman, Berna Bozkurt
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2024, 281 (02) : 1025 - 1030
  • [42] Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy
    Kim, Hee Sung
    Yom, Cha Kyong
    Kim, Hee Jeong
    Lee, Jong Won
    Sohn, Jin Hee
    Kim, Jun Ho
    Park, Yong Lai
    Ahn, Sei Hyun
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (03) : 777 - 788
  • [43] Management of osteoporosis in women with breast cancer
    Shapiro, Charles L.
    BREAST CANCER MANAGEMENT, 2020, 9 (02)
  • [44] Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer
    Honig, SF
    SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS), 2001, 949 : 345 - 348
  • [45] Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
    Hale, Michael J.
    Howell, Anthony
    Dowsett, Mitch
    Cuzick, Jack
    Sestak, Ivana
    BREAST, 2020, 54 : 216 - 221
  • [46] Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review
    Iqbal, Javaid
    Ginsburg, Ophira M.
    Wijeratne, Thiwanka D.
    Howell, Anthony
    Evans, Gareth
    Sestak, Ivana
    Narod, Steven A.
    CANCER TREATMENT REVIEWS, 2012, 38 (04) : 318 - 328
  • [47] Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast Cancer
    Koji Yamazawa
    Yukimasa Miyazawa
    Masato Suzuki
    Maki Wakabayashi
    Hiroshi Kaku
    Hideo Matsui
    Souei Sekiya
    Surgery Today, 2006, 36 : 41 - 46
  • [48] Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer
    Yamazawa, K
    Miyazawa, Y
    Suzuki, M
    Wakabayashi, M
    Kaku, H
    Matsui, H
    Sekiya, S
    SURGERY TODAY, 2006, 36 (01) : 41 - 46
  • [49] Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance
    Tabarestani, Sanaz
    Ghaderian, Sayyed Mohammad Hossein
    Rezvani, Hamid
    Mirfakhraie, Reza
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [50] Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment
    Li, Bailiang
    Li, Yang
    Wang, Xiao-Yu
    Yan, Zi-Qiao
    Liu, Huidi
    Liu, Gui-Rong
    Liu, Shu-Lin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (02): : 726 - 737
12345